The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.

The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.

Acute Myeloid Leukemia (AML) is an aggressive malignancy which leads to marrow failure, and ultimately death. There is a desperate need for new therapeutics for these patients. Ribonucleotide reductase (RR) is the rate limiting enzyme in DNA synthesis. Didox (3,4-Dihydroxybenzohydroxamic acid) is a...

Full description

Bibliographic Details
Main Authors: Guerry J Cook, David L Caudell, Howard L Elford, Timothy S Pardee
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4234372?pdf=render

Similar Items

Similar Items